P

Premier Neurology | Greer, SC

Research site
(Unclaimed)
Location
420 The Parkway, Suite N, Greer, South Carolina, United States of America
Site insights

Top conditions

Multiple Sclerosis (6 trials)

Sclerosis (6 trials)

Chronic Progressive Multiple Sclerosis (3 trials)

Migraine Disorders (2 trials)

Top treatments

Ocrelizumab
Satralizumab
Erenumab
LY3541860
Teriflunomide
Fenebrutinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

8 of 9
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis (Ocarina II)

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) a...

Active, not recruiting
Primary Progressive Multiple Sclerosis
Relapsing Multiple Sclerosis
Drug: Methylprednisolone IV
Drug: Ocrelizumab SC
Locations recently updated

The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and...

Enrolling
Multiple Sclerosis
Drug: Placebo
Drug: LY3541860

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible parti...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Placebo

This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple s...

Enrolling
Multiple Sclerosis, Primary Progressive
Drug: Ocrelizumab
Drug: Placebo

This is a randomized, double blind, controlled, parallel group, multicenter study to evaluate efficacy, safety and pharmacokinetics of a higher dose...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab
Drug: Methylprednisolone

The main objective of the study is to evaluate the efficacy of satralizumab compared with placebo based on time from randomization to the first occur...

Enrolling
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Other: Placebo
Drug: Satralizumab

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to participants...

Active, not recruiting
Multiple Sclerosis (MS)
Drug: Ocrelizumab
Drug: rHuPH20

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolesc...

Enrolling
Acute Treatment of Migraine
Drug: Rimegepant / BHV3000

Trial sponsors

Roche logo

Roche (6 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems